血清miR-145及MMP-2水平预测三阴性乳腺癌新辅助化疗后病理完全缓解的价值
Value of serum miR-145 and MMP-2 levels in predicting pathological complete response after neoadjuvant chemotherapy for triple-negative breast cancer
谷振芳 1胡东玉 1徐保彬 1李伟 1张春梅1
作者信息
- 1. 济宁医学院附属医院肿瘤科,济宁 272100
- 折叠
摘要
目的 探讨血清miR-145及基质金属蛋白酶-2(matrixmetallo proteinase-2,MMP-2)水平预测三阴性乳腺癌(triple-negative breast cancer,TNBC)新辅助化疗后病理完全缓解(pathologic complete response,pCR)的价值.方法 前瞻性纳入2022年1月至2023年12月于济宁医学院附属医院就诊并进行新辅助化疗的125例TNBC患者作为研究对象,并纳入与观察组年龄相匹配的130例同期在本院进行体检的健康人作为健康对照组.采用实时荧光定量聚合酶链反应对所有研究对象血清miR-145水平进行检测.采用酶联免疫吸附实验法测定患者血清MMP-2的水平.新辅助化疗后,根据Miller-Payne(MP)分级标准对患者进行疗效评估,分为pCR组和非pCR组.结果 TNBC患者血清miR-145水平为1.49±0.27,显著低于健康对照组的 2.79±0.49,差异有统计学意义(t=20.33,P＜0.001);TNBC 患者血清 MMP-2 水平为(153.07±38.36)ng/mL,显著高于健康对照组的(84.38±12.63)ng/mL,差异有统计学意义(t=26.13,P＜0.001).新辅助化疗后非pCR患者的治疗前血清miR-145水平为1.36±0.21,显著低于pCR组的(1.74±0.20),差异有统计学意义(t=9.93,P＜0.001);新辅助化疗后非pCR患者的治疗前血清MMP-2水平为(169.57±30.45)ng/mL,显著高于pCR组的(121.61±31.79)ng/mL,差异有统计学意义(t=8.24,P＜0.001).Pearson相关性分析结果显示,TNBC患者治疗前血清miR-145与MMP-2水平呈显著负相关关系(r=-0.47,P＜0.001).ROC曲线分析结果显示,治疗前血清miR-145、MMP-2水平预测TNBC新辅助化疗后pCR的灵敏度和特异度分别为82.9％和74.4％、45.1％和99.8％,两者联合预测TNBC新辅助化疗后pCR的灵敏度和特异度分别为84.1％和88.4％.结论 血清miR-145 及MMP-2水平与TNBC患者新辅助化疗后的疗效有关,且两者联合应用有一定预测价值.
Abstract
Objective To investigate the value of serum miR-145 and matrixmetallo proteinase-2(MMP-2)levels in predicting pathologic complete response(pCR)after neoadjuvant chemotherapy in triple-negative breast cancer.Methods 125 patients with triple-negative breast cancer who received neoadjuvant chemotherapy in the Hospital from Jan.2022 to Dec.2023 were prospectively included as the study objects,and 130 healthy peo-ple matching the age of the case group who underwent physical examination in our hospital during the same period were included as the healthy control group.Real-time fluorescence quantitative polymerase chain reaction was used to detect the serum miR-145 level of all subjects.Serum MMP-2 levels were determined by enzyme-linked immuno-sorbent assay(ELISA).After neoadjuvant chemotherapy,patients were evaluated according to Miller-Payne(MP)grading criteria and divided into pCR group and non-PCR group.Results The serum miR-145 level in patients with tertiary breast cancer was 1.49±0.27,which was significantly lower than that in healthy control group(2.79±0.49),with statistical significance(t=20.33,P＜0.001).The serum MMP-2 level in triple negative breast cancer pa-tients was(153.07±38.36)ng/mL,which was significantly higher than that in healthy control group(84.38±12.63)ng/mL,and the difference was statistically significant(t=26.13,P＜0.001).After neoadjuvant chemotherapy,the se-rum miR-145 level in non-PCR patients before treatment was 1.36±0.21,which was significantly lower than that in pCR group(1.74±0.20),with statistical significance(t=9.93,P＜0.001).After neoadjuvant chemotherapy,the se-rum MMP-2 level in non-PCR patients before treatment was(169.57±30.45)ng/mL,which was significantly higher than that in pCR group(121.61±31.79)ng/mL,and the difference was statistically significant(t=8.24,P＜0.001).Pearson correlation analysis showed that there was a significant negative correlation between serum miR-145 and MMP-2 levels in patients with triple-negative breast cancer before treatment(r=-0.47,P＜0.001).ROC curve analy-sis results showed that serum miR-145 and MMP-2 levels before treatment predicted the sensitivity and specificity of pCR after neoadjuvant chemotherapy for triple-negative breast cancer were 82.9％and 74.4％,45.1％and 99.8％,respectively.The sensitivity and specificity of pCR after neoadjuvant chemotherapy for triple-negative breast cancer were 84.1％and 88.4％,respectively.Conclusion Serum miR-145 and MMP-2 levels are related to the efficacy of neoadjuvant chemotherapy in patients with triple-negative breast cancer,and the combined applica-tion of the two has certain predictive value.
关键词
三阴性乳腺癌/新辅助化疗/病理完全缓解/miR-145/基质金属蛋白酶-2Key words
Triple-negative breast cancer/Neoadjuvant chemotherapy/Pathological complete remis-sion/miR-145/Matrix metalloproteinase-2引用本文复制引用
基金项目
济宁市重点研发计划(软科学)项目(2022JNZC039)
出版年
2024
NETL
NSTL
万方数据